-- 奥本海默周三发布的研究报告指出，Dynatrace (DT) 第四季度业绩有望稳健，营收增长加速推动业绩预期上调。 分析师写道，渠道调查显示，市场竞争格局稳定，消费者需求稳定，且交易渠道储备充足，这些都预示着第四季度业绩良好。 该券商表示，对 Dynatrace 的销售执行力、专注于拓展核心企业客户群以及充分利用 Grail、Smartscape 和 Dynatrace Intelligence 等产品充满信心。 报告指出，业绩能否进一步上调取决于管理层能否展现出实现 20% 营收增长的路径。 该券商重申了对 Dynatrace 股票的“跑赢大盘”评级和每股 53 美元的目标价。
Price: $36.07, Change: $+0.35, Percent Change: +0.98%
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.